IDARUCIZUMAB FOR REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONS
Charles V. Pollack(Hospital of the University of Pennsylvania), Jeffrey I. Weitz(McMaster University Medical Centre), Frank W. Sellke(Brown University), Menno V. Huisman(Leiden University Medical Center), Elaine Hylek, Stephan Glund(Boehringer Ingelheim (Germany)), Thorsten Steiner(Heidelberg University), Jerrold H. Levy(Duke University), Pieter W. Kamphuisen(University Medical Center Groningen), Fredrik Gruenenfelder(Boehringer Ingelheim (Germany)), Bushi Wang(Boehringer Ingelheim (United States)), John W. Eikelboom(Population Health Research Institute), Richard A. Bernstein(Northwestern University), Paul Reilly(Boehringer Ingelheim (United States)), Joachim Stangier(University of Bonn), Jörg Kreuzer(Boehringer Ingelheim (Germany)), CW Kam(Boehringer Ingelheim (Germany))
Cited by 2
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
|New England Journal of Medicine|2017|2.4k
Cryptogenic Stroke and Underlying Atrial Fibrillation
|New England Journal of Medicine|2014|2.2k